Quick Search
Products Tissue Array, Human, BioAssay(TM) Bladder carcinoma, transitional cell carcinoma, grade I~III with normal
| Catalogue number: | T5596-1461 |
| Reactivities: | Human |
| Applications: | Immunohistochemistry |
| Size: | 1 Array |
| References: | 1. Kazuhiko Mishima, et al. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol March (2006). (paper). 2. Mohammad Saleem, Vaqar Mustafa Adhmai, Weixiong Zhong, B. Jack Longley, Chen-Yong Lin, Robert B. Dickson, Shannon Reagan-Shaw, David F. Jarrard, and Hasan Mukhtar. A novel biomarker for staging human prostate adenocarcinoma: Overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activiator inhibitor-1. Cancer Epidemiol Bioimarker Prev 15(2) 217-227, February (2006). (paper) 3. Chen-Feng Qi, et al. Expression of the cyclin-dependent kinase inhibitor p27 and its deregulation in mouse B-cell lymphomas. Leukemia Research (30) 153-163, February (2006). (paper). 4. Tin Lab Lee, et al Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas. Mol Cancer Ther 5(1) 8-19, January (2006). (paper) 5. N Chen, et al Tumor-suppression function of transcription factor USF2 in prostate carcinogenesis. Oncogene 1-9 (2005) (paper). 6. Ming Li, et al. Overexpression of 5-Lipoxygenase and Cyclooxygenase2 in Hamster and Human Oral Cancer and Chemopreventive Effects of Zileuton and Celecoxib. Clinical Cancer Research Vol. 11, 2089-2096, (2005). (paper). 7. Min Yan, et al. 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGFg induced suppressor of human gastrointestinal cancers. PNAS Vol.101, No. 50, 17468-17473 (2004). (paper) 8. Luping Wang, et al. Extracellular matrix protein1 (ECM1) is over-expressed in malignant epithelial tumors. Cancer Letter Vol. 200 75-67 (2003) (paper). 9. Holger Moch, Jet al , Tissue microarrays: what will they bring to molecular and anatomic pathology. Advances in Anatomic Pathology Vol.8, No.1,14-20, (2001). 10. Ronald Simon, Jan Richter, Urs Wagner, et al., High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res. 61:4514-4519, (2001). 11. Mark A. Rubin. Use of laser capture microdissection, cDNA microarrays, and tissue microarrays in advancing our understanding of prostate Cancer. J. Pathol. 195:80-86, (2001). 12. Olli-P. Kallioniemi, Urs Wagner, Juha Kononen and Guido Sauter, Tissue microarray technology for high-throughput molecular profiling of cancer. Human Molecular Genetics Vol.10, No.7, 657-662, (2001). 13. David L. Rimm, Robert L. Camp, Lori A.Charette, et al., Tissue microarray: a new technology for amplification of tissue resources. The Cancer Journal Vol.7, No.1, (2001). 14. Lukas Bubendorf, Antonio Nocito, Holger Moch and Guido Sauter, Tissue microarray (TMA) technology: miniaturized pathology archives for high -Throughput in situ studies. J. Pathol. 195:72-79, (2001). 15. Chad R. Englert, Galina V. Baibakov, and Michael R. Emmert-Buck, Cancer Res. 60:1526-1530, (2000). 16. F. von Eggeling, H. Davies, L. Lomas, W. Fiedler, K. Junker, U. Claussen and G. Ernst, Tissue-specific microdissection coupled with proteinchip array technologies: applications in cancer research. Biotechniques Vol.29, No.5, 1066-1070, (2000). 16. Olivier Braissant and Walter Wahli, A simplified in situ hybridization protocol using non-radioactively labeled probes to detect abundant and rare mRNAs on tissue sections. Biochemica No.1, 10-16, (1998). |
Get the Best Promotions
